Fermentation properties and potential prebiotic activity of Bimuno[®] galacto-oligosaccharide (65 % galacto-oligosaccharide content) on *in vitro* gut microbiota parameters

Roberta Grimaldi¹*, Jonathan R. Swann², Jelena Vulevic³, Glenn R. Gibson¹ and Adele Costabile⁴

¹Department of Food and Nutritional Sciences, University of Reading, Reading RG6 6AP, UK

²Division of Computational and Systems Medicine, Imperial College, London SW7 2AZ, UK

 3 Clasado Research Services Ltd, Science & Technology Centre, University of Reading, Reading RG6 6BZ, UK

⁴Life Sciences Department, Health Sciences Research Centre, Whitelands College, University of Roehampton, London SW15 4JD, UK

(Submitted 26 February 2016 - Final revision received 19 April 2016 - Accepted 7 May 2016 - First published online 8 June 2016)

Abstract

Prebiotic oligosaccharides have the ability to generate important changes in the gut microbiota composition that may confer health benefits to the host. Reducing the impurities in prebiotic mixtures could expand their applications in food industries and improve their selectivity and prebiotic effect on the potential beneficial bacteria such as bifidobacteria and lactobacilli. This study aimed to determine the *in vitro* potential fermentation properties of a 65% galacto-oligosaccharide (GOS) content Bimuno[®] GOS (B-GOS) on gut microbiota composition and their metabolites. Fermentation of 65% B-GOS was compared with 52% B-GOS in pH- and volume-controlled dose–response anaerobic batch culture experiments. In total, three different doses (1, 0·5 and 0·33 g equivalent to 0·1, 0·05 and 0·033 g/l) were tested. Changes in the gut microbiota during a time course were identified by fluorescence *in situ* hybridisation, whereas small molecular weight metabolomics profiles and SCFA were determined by ¹H-NMR analysis and GC, respectively. The 65% B-GOS showed positive modulation of the microbiota composition during the first 8 h of fermentation with all doses. Administration of the specific doses of B-GOS induced a significant increase in acetate as the major SCFA synthesised compared with propionate and butyrate concentrations, but there were no significant differences between substrates. The 65% B-GOS in syrup format seems to have, in all the analysis, an efficient prebiotic effect. However, the applicability of such changes remains to be shown in an *in vivo* trial.

Key words: Prebiotic activity: Bimuno[®] galacto-oligosaccharides: Microbiota composition: Fluorescence *in situ* hybridisation: SCFA

In vitro and in vivo studies involving prebiotic oligosaccharides have been carried out using inulin and its fructooligosaccharide (FOS) derivatives, as well as various galactooligosaccharides (GOS). It has been shown that these food ingredients have the ability to improve selectively the growth of bifidobacteria, and consequently lead to important changes in the gut microbiota composition that may confer health benefits to the host. To date, GOS has been associated with numerous health benefits such as low energy content, insulin-independent metabolism and stimulation of growth and metabolism of specific colonic microbiota. The two main mechanisms by which this is achieved are through the production of SCFA from its fermentation and the selective enhancement of beneficial gut organisms⁽¹⁾. GOS can be defined as a mixture of the end products of lactose breakdown by β -galactosidases, containing two to eight saccharide units, with a terminal glucose unit⁽²⁾. These mixtures can be complex and their structures are often

imperfectly characterised. They tend to be mixtures of β -1,3, β -1,4 and β -1,6 linkages with degrees of polymerisation ranging from two to five. A characteristic of GOS is that the set of structures present depends on the source of the enzyme used to bring about synthesis. The structural and functional relationship of GOS plays a role in targeting the *Bifidobacterium* genus⁽³⁾. Another important aspect is the presence of impurities such as monosaccharaides, disaccharides or metabolic products from purification steps. Removing these compounds can lead to a mixture with a GOS content as high as possible that can be better used to study fermentation and structural properties of novel prebiotics in in vitro experiments. In addition, purified Bimuno[®] GOS (B-GOS) mixture might have significantly increased interest in production and application in various food and pharmaceutical processes, especially if the prebiotic is incorporated directly into food such as diabetic or low-energy foods. Reducing monosaccharides and disaccharides such as

Abbreviations: B-GOS, Bimuno[®] galacto-oligosaccharide; GOS, galacto-oligosaccharide.

^{*} Corresponding author: R. Grimaldi, email r.grimaldi@pgr.reading.ac.uk

glucose, galactose and lactose from the mixture might help minimise their impact on consumers, particularly by taking into account lactose intolerance. Several techniques have been suggested in order to obtain high recovery of GOS, but all of them have some limitations⁽⁴⁾. B-GOS (Bimuno[®] 52% GOS content; Clasado Biosciences Ltd) refers to prebiotic GOS compounds that have multiple biological health activities within the colonic environment. It is produced from the activity of galactosidase enzymes isolated from Bifidobacterium bifidum NCIMB 41171⁽⁵⁾. The method for B-GOS purification has been studied by Goulas et al.⁽⁶⁾ in order to reduce the amount of free glucose and galactose produced during its synthesis, and it led to the removal of 92% of glucose by fermentation with Saccharomyces cerevisiae. The bifidogenic properties of B-GOS have been investigated in vitro and in vivo. Tzortzis et al.⁽⁷⁾ showed in vitro and in a pig trial the prebiotic potential of GOS. In this study, it was established that B-GOS prebiotic activity was relevant in terms of increase in bifidobacteria numbers, SCFA production and decreased pH, compared with other prebiotics such as inulin and other GOS types⁽⁷⁾. B-GOS has also been tested in healthy volunteers, clinical conditions that have a purported microbial aetiology such as irritable bowel syndrome, traveller's diarrhoea and obesity, and on cognitive functions⁽⁸⁻¹³⁾. This study aimed to determine the potential prebiotic activity of a purified 65% GOS content B-GOS,

Methods

Substrates

The two B-GOS products, supplied by Clasado BioSciences Ltd, used in this study were produced from the activity of galactosyltransferases from *B. bifidum* NCIMB 41171 on lactose⁽¹⁴⁾. Both were used in syrup form. The B-GOS mixtures consisted of (w/w) 52% GOS, 8% lactose, 22% glucose, 16·5% galactose and 65% GOS, 10·1% lactose, 22% glucose, 1·8% galactose, respectively.

compared with 52% GOS content B-GOS, used as positive

control in in vitro dose-response batch cultures.

Faecal inoculation

Experiments were carried out using fresh faecal samples from three healthy donors (one female aged 26 years and two males aged 25 and 31 years, respectively) who were free of any metabolic and gastrointestinal diseases, were not taking probiotic or prebiotic supplements and had not taken antibiotics for 6 months before faecal sample donation. All donors then provided written informed consent, and filled in a standard questionnaire to collect information regarding health status, drug use, clinical anamnesis and lifestyle factors. This study was approved by The University of Reading Research Ethics Committee (UREC 15/20). Faecal samples were placed in an anaerobic jar (AnaeroJarTM 2.5L; Oxoid Ltd) including a gasgenerating kit (AnaeroGenTM; Oxoid). Samples were diluted 1/10 w/w in anaerobic PBS (0·1 mol/l phosphate buffer solution, pH 7·4) and homogenised (Stomacher 400; Seward) for 2 min at 240 paddle beats/min. Samples were added to anaerobic fermenters within 15 min of voiding.

In vitro batch culture fermentation

This method was previously described by Rycroft *et al.*⁽¹⁵⁾. B-GOS were added at concentrations shown in Table 1 before adding 5 ml of faecal slurry (final concentration of 1%). An extra vessel with no added carbohydrate source was also included as a negative control. The pH was maintained in the range of $6\cdot7-6\cdot9$ via pH controllers (Fermac 260; Electrolab) and automatically adjusted by adding 0.5 mM-NaOH and HCl to the vessels when required. The pH and temperature mimicked the conditions of the distal region of the human large intestine. Batch culture fermentations were run for 24 h, and the samples ($3\cdot5$ ml from each vessel) were collected at 0, 4, 8 and 24 h for analysis of bacterial populations and metabolite production. Fermentation experiments were performed in triplicate.

Bacterial enumerations by fluorescence in situ hybridisation

Differences in bacterial populations were assessed by fluorescence *in situ* hybridisation (FISH) with oligonucleotide probes designed to target specific diagnostic regions of 16S rRNA, as previously described⁽¹⁶⁾. The probes were commercially synthesised and labelled at the 5' end with the fluorescent dye Cy3 (Sigma-Aldrich) as reported in Table $2^{(17-22)}$. Numbers of specific and total bacteria were determined using the following equation: DF×ACC×6732·42×50×DF sample, where DF is the dilution factor (300/375 = 0.8), ACC is the average cell count of fifteen fields of view and DF sample refers to the dilution of sample used with a particular probe or stain. The figure 6732·42 refers to the area of the well divided by the area of the field of view and the factor 50 takes the cell count back to per millilitre of sample.

SCFA analysis

Production of SCFA was determinate using GC as previously described⁽²³⁾. Peaks were integrated using Agilent ChemStation software (Agilent Technologies), and SCFA content was quantified by single-point internal standard method. Peak identity and internal response factors were determined using a 20-mm calibration cocktail including acetic, propionic, iso-butyric, butyric, iso-valeric, valeric, caproic and caprylic acids.

Table 1. Doses of the Bimuno[®] galacto-oligosaccharide (B-GOS) syrups tested (equivalent to 0.1, 0.05 and 0.033 g/l) in 100 ml working volume vessels during 24 h of fermentation in pH- and volume-controlled batch fermentation experiments

Vessel	Treatment	Syrup (g)	DM	GOS in 100 ml			
1	B-GOS (52% GOS content)	2.66	2	1			
2	B-GOS (52 % GOS content)	1.33	1	0.5			
3	B-GOS (52 % GOS content)	0.88	0.66	0.33			
4	B-GOS (65% GOS content)	2.05	1.54	1			
5	B-GOS (65% GOS content)	1.02	0.77	0.5			
6	B-GOS (65 % GOS content)	0.68	0.51	0.33			
7	Negative control (only faeces)						

Table 2. Oligonucleotide probes used in the study for fluorescence in situ hybridisa	tion analysis of bacterial populations
--	--

Probe name and sequence (5'-3')	Target species	Hybridisation-washing temperature (°C)	References
Bif164 CATCCGGCATTACCACCC	Most Bifidobacterium spp. and Parascardovia denticolens	50–50	(20)
Bac303 CCAATGTGGGGGGACCTT	Most Bacteroides sensu stricto and Prevotella spp.; all Parabacteroides; Barnesiella viscericola and Odoribacter splanchnicus	46–48	(21)
Lab158 GGTATTAGCAYCTGTTTCCA	Most Lactobacillus, Leuconostoc and Weissella spp.; Lactococcus lactis; all Vagococcus, Enterococcus, Melissococcus, Tetragenococcus, Catellicoccus, Pediococcus and Paralactobacillus spp.	50–50	(22)
Chris150 TTATGCGGTATTAATCTYCCTTT	Most members of <i>Clostridium</i> cluster I; all members of <i>Clostridium</i> cluster II; <i>Clostridium tyrobutyricum</i> ; <i>Adhaeribacter aquaticus</i> and <i>Flexibacter canadensis</i> (family <i>Flexibacteriaceae</i>); (Eubacterium) <i>combesii</i> (family <i>Propionibacteriaceae</i>)	50–50	(23)
Erec 482 GCTTCTTAGTCARGTACCG	Most members of <i>Clostridium</i> cluster XIVa; <i>Syntrophococcus</i> <i>sucromutans</i> , (Bacteroides) <i>galacturonicus</i> and (Bacteroides) <i>xylanolyticus</i> , <i>Lachnospira pectinschiza</i> and <i>Clostridium</i> <i>saccharolyticum</i>	50–50	(23)
EUB338 I GCTGCCTCCCGTAGGAGT	Total bacteria	46–48	(24)
EUB338 II GCAGCCACCCGTAGGTGT	Total bacteria	46–48	(24)
EUB338 III GCTGCCACCCGTAGGTGT	Total bacteria	46–48	(24)
Rrec584 TCAGACTTGCCGYACCGC	Roseburia – Eubacterium rectale (a component of cluster XIVa)	50–50	(25)
Prop853 ATTGCGTTAACTCCGGCAC	Clostridium cluster IX	50–50	(25)

Metabolite analysis by ¹H-NMR

Fermentation supernatants from all time points were defrosted, vortexed and centrifuged at 599g for 5 min. Supernatants were filtered using 0.22-µm low protein binding durapore polyvinylidene fluoride membrane (Millex; EMD Millipore) and 400 µl was transferred into fresh eppendorf tubes. Filtered samples were then combined with 200 µl of phosphate buffer (0.2 м (pH 7.4) in D₂O plus 0.001 % trimethylsilyl propionate (TSP)). The mixture was vortexed and centrifuged at 1136 g for 10 min and then 550 µl was transferred into 5-mm NMR tubes for analysis. All NMR spectra were acquired on Bruker Avance DRX 500 MHz NMR Spectrometer (Bruker BioSpin) operating at 500 MHz. They were acquired using a standard 1-dimensional (1D) pulse sequence (recycle delay (RD)-90°-t1-90°-tm-90°-acquire free induction decay (FID)) with water suppression applied during RD of 2s, a mixing time tm of 100 ms and a 90 pulse set at 7.70 µs. For each spectrum, a total of 128 scans were accumulated into 64 k data points with a spectral width of 12.001 parts per million. The FID were multiplied by an exponential function corresponding to 0.3 Hz line broadening. All spectra were manually phased, baseline corrected and calibrated to the chemical shift of TSP (δ 0.00). Spectra were digitised using an in-house MATLAB (version R2014a; The Mathworks Inc.) script. The spectral region containing the water resonance was removed to minimise distortions in the baseline arising from imperfect water saturation. Principal component analysis (PCA) was performed with Pareto scaling using scripts provided by Korrigan Sciences Ltd.

Statistical analysis

All statistical tests were performed using GraphPad Prism (version 5.0; Graph-Pad Software). A two-way ANOVA test was

used to compare dose, substrates and time-dependent effects. When there was no significant effect, one-way ANOVA tests and paired *t* tests, including *post boc* tests appropriate for the individual data sets (Bonferroni post-test with significance set at P < 0.05), were used for bacterial counts and organic acid concentrations.

Results

SCFA analysis

Our results showed acetate as the dominant SCFA produced for both substrates with significant differences between 4 and 8 h of fermentation using 65 % B-GOS at 0.033 g/l (P < 0.01) (Table 3). In particular, there was a clear dose-response effect during the first 4h of fermentation. However, no significant differences were observed between the two substrates at the same dose. The dose-response effect was also confirmed by ¹H-NMR data. PCA revealed a clear trajectory over time, showing a clear separation between 0 and 4 h with acetate as main component influencing variation through time (Fig. 1). Significant decreases in propionate concentration throughout fermentation were observed, mainly between 8 and 24 h of fermentation (P < 0.01). None of the substrates generated major changes in butyrate production (Table 3). Two-way ANOVA data analyses did not show significant differences on SCFA production between the two substrates.

Changes in bacterial populations

A significant increase in bifidobacteria was observed with 52% B-GOS 0.5 and 0.33 g (equivalent to 0.05 and 0.033 g/l) between time 0 and 24 h and with 65% B-GOS (P<0.05) at same doses at all time points tested (P<0.05) (Table 4).

Table 3. SCFA production by GC in the pH-controlled and volume-controlled batch cultures at 0, 4, 8 and 24 h of fermentation⁺ (Mean of the data of three experiments and standard deviations)


		Acetate (mм)		Propionate (mм)		Butyrate (mм)		Branched (тм)		Total (mм)		
Substrates	Time (h)	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
	0	26.77	22.13	6.50	7.25	4.63	5.11	15.60	17.26	53.49	51.53	
52 % B-GOS (1 g)	4	30.96	18.64	6.43	8.32	4.44	6.92	16.08	11.36	57.92	56.63	
	8	28.39	6.91	2.59	0.76	0.95	0.47	3.13	1.42	35.06	6.89	
	24	17.14	0.1	1.06	0.1	0.55	0.1	0.22	0.1	18.98	0.1	
	0	17.27	8.37	3.63	3.42	2.57	2.61	8.81	9.28	32.28	23.49	
52 % B-GOS (0.5 g)	4	28.33	19.27	4.67	6.09	2.29	3.41	7.71	11.36	43.01	40.13	
	8	31.25	15.30	2.11	1.65	0.80	0.51	1.37	0.98	35.52	18.34	
	24	20.3	0.1	0.91	0.1	0.39	0.1	0.23	0.1	21.84	0.1	
	0	11.41	8.94	2.26	1.92	1.63	1.52	5.74	5.89	21.04	16.22	
52 % B-GOS (0·33 g)	4	17.43	19.16	4.56	6.62	1.75	2.63	4.62	7.01	28.36	35.33	
	8	26.54	26.11	4.47	5.63	1.24	1.57	1.13	0.92	33.37	35.22	
	24	26.24	0.1	0.75	0.1	0.24	0.1	0.17	0.1	27.39	0.1	
	0	18.29	10.59	2.33	2.31	1.32	1.39	4.69	4.87	26.63	19.12	
65 % B-GOS (1 g)	4	38.42	22.17	4.65	4.45	1.42	1.91	4.47	5.65	48.97	34.11	
	8	43.37	28.55	6.81	5.19	1.21	0.99	1.47	1.15	52.82	33.81	
	24	6.78	0.1	0.73**	0.1	0.4	0.1	0.39	0.1	8.31	0.1	
	0	17.94	7.95	2.01	1.94	0.92	0.97	3.42	3.61	24.29	14.33	
65 % B-GOS (0.5 g)	4	30.61	20.92	3.97	3.69	1.27	1.59	3.19	3.95	39.03	30.10	
	8	24.43	11.06	3.32	2.47	0.72	0.56	1.18	0.81	29.65	13.96	
	24	21.51	0.1	0.61**	0.1	0.50	0.1	0.28	0.1	22.89	0.1	
	0	12.29	5.37	1.33	1.14	0.58	0.6	2.1	2.31	16.3	9.21	
65 % B-GOS (0-33 g)	4	24.68	15.65	3.39	3.19	0.84	1.03	2.14	2.65	31.05	22.49	
	8	27.18**	12.41	3.98	2.72	0.71	0.48	1.25	1.02	33.12	15.48	
	24	20.88	0.1	1.18*	0.1	0.97	0.1	0.77	0.1	23.79	0.1	
	0	5.28	5.69	0.71	0.51	0.36	0.32	1.15	1.25	7.5	5.34	
Negative control	4	8.68	5.25	1.68	0.97	0.61	0.47	1.3	1.66	12.31	8.28	
5	8	18.82	8.74	2.71	1.47	0.67	0.12	0.97	0.84	23.17	10.64	
	24	18.43	0.1	2.37	0.1	1.47	0.1	0.49	0.1	22.76	0.1	

B-GOS, Bimuno® galacto-oligosaccharide.

* Significantly different from 0 h with P < 0.05.

** Significantly different from 0 h with P<0.01 (one-way ANOVA).

† 52 % B-GOS and 65 % B-GOS at doses 1, 0.5 and 0.33 g (equivalent to 0.1, 0.05 and 0.033 g/l).



484

Table 4 Bacteria	l arouns detected	by fluorescence	in situ	hybridisation	in the	nH-cc

 Table 4. Bacterial groups detected by fluorescence in situ hybridisation in the pH-controlled and volume-controlled batch cultures at 0, 4, 8 and 24 h of fermentation*

 (Mean of the data of three experiments and standard deviations; n 3)

						Ва	cterial p	opulation	(log10 d	cells/ml)					
Probes		52 % B- 1 g	52 % B-GOS 52 % B-GOS 1 g 0.5 g			52 % B-GOS 0·33 g		65 % B-GOS 1 g		65% B-GOS 0∙5 g		65 % B-GOS 0∙33 g		NC	
	Time point (h)	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Eub338 I-II-III	0	9.24	0.09	9.13	0.11	9.22	0.11	9.24	0.11	9.27	0.12	9.23	0.1	9·19	0.08
	4	9.11	0.17	9.15	0.18	9.14	0.44	9.39	0.14	8.9	0.14	9.35	0.07	9.04	0.31
	8	9.16	0.13	9.49	0.23	9.05	0.41	9.52	0.1	8.92	0.1	9.46	0.04	9.2	0.59
	24	9.14	0.01	9.33	0.03	9.1	0.05	8∙94 ^{a,c}	0.07	9.21	0.01	9.56ª	0.04	8∙95 ^a	0.02
Lab158	0	7.63	0.09	7.48	0.11	7.55	0.05	7.52	0.07	7.54	0.15	7.47	0.06	7.48	0.06
	4	7.57	0.05	7.64	0.16	7.77	0.27	7.78	0.14	7.73	0.12	7.31	0.29	7.54	0.2
	8	7.74	0.1	8.05	0.11	7.6	0.36	7.98	0.27	8·21	0.56	7.66	0.12	7.55	0.4
	24	8.39 ^{<i>a</i>,b,<i>c</i>}	0.02	7.70 ^c	0.01	7.94 ^a	0.07	7.94 ^a	0.09	7.68	0.06	7.85 ^a	0.05	7.29 ^a	0.08
Bif164	0	8.61	0.28	8.7	0.17	8.58	0.26	8.45	0.35	8.63	0.21	8.47	0.3	8.68	0.21
	4	8.73	0.33	9.1	0.22	8.79	0.67	8.86 ^b	0.2	8.75	0.19	8.47	0.4	8.45	0.31
	8	8.93	0.29	8.87	0.61	8.95	0.63	9.12	0.21	9.25 ^{a,b}	0.04	9.31 ^{a,b}	0.1	8.53	0.13
	24	9.2	0.06	9.31 ^a	0.03	9.19 ^a	0.08	9.12	0.21	9.2 ^{a,b}	0.07	9.24 ^a	0.04	8.25	0.07
Bac303	0	8.26	0.16	8.23	0.35	8.27	0.33	8.33	0.25	8.33	0.3	8.2	0.19	8.26	0.29
	4	8.07	0.55	8.41	0.53	8.09	0.86	8.49	0.15	7.94 ^a	0.26	8.39	0.12	7.75	0.83
	8	7.33	0.64	7.83	0.82	8.11	0.66	8.31	0.46	7.88	0.32	8.63	0.19	6.71ª	0.37
	24	7.78 ^a	0.05	8.39	0.15	7.06 ^a	0.2	7.94 ^b	0.03	8.41	0.06	8.29	0.04	8.39 ^{a,c}	0.2
Erec482	0	8.35	0.16	8.34	0.13	8.42	0.03	8.34	0.06	8.38	0.09	8.3	0.04	8.32	0.05
	4	8·29	0.12	8.39	0.15	8·17	0.31	8.4	0.21	8.36	0.2	8·24	0.34	8.08	0.43
	8	7.85	1.21	7.92	1.42	7.88	1.22	7.91	1.36	8.45	0.08	8.38	0.38	7.98	0.76
	24	8-85 ^{a,b}	0.37	8.65 ^a	0.06	7.94 ^a	0.04	8.58 ^a	0.01	8.59 ^a	0.01	8.56 ^a	0.04	8.06 ^a	0.05
Rrec584	0	8.34	0.25	8.24	0.08	8.06	0.54	8.15	0.3	8·17	0.17	8.28	0.09	8.34	0.04
	4	7.54	1.04	8.13	0.3	7.85	0.59	8·2	0.41	7.29	0.86	7.77	0.62	7.78	0.69
	8	7.06	0.87	7.47	0.74	7.37 ^a	0.78	7.71	0.98	7.21	0.78	7.6	0.56	7.66 ^a	0.21
	24	7·2	0.02	7.14 ^{a,b}	0.05	6.92	0.01	7.78	0.14	7.23 ^a	0.06	8.51ª	0.03	7.54 ^a	0.2
Chis150	0	5.83	0.2	5.73	1.1	5.83	0.2	5.73	1.1	5.93	0.3	5.73	1.1	5.73	1.1
	4	5.86	0.04	6.34	0.5	5.79	0.1	6.56	0.6	6.11	0.2	6.2	0.3	5.9	0.1
	8	6.03	0.1	6.74	1	6.53	1	6.80	1.1	6.92	1.3	7.24	0.8	5.87	0.2
	24	5.73	0.02	5.73	0.05	7.45	0.01	5.73	0.2	6.43	0.03	5.73	0.01	5.73	0.01
Prop853	0	7.98	0.18	7.97	0.27	8.05	0.22	8.18	0.26	8.16	0.22	8.08	0.22	8.04	0.06
•	4	8.04	0.28	7.97	0.02	7.81	0.47	8.02	0.09	8.02	0.05	8.11	0.09	7.99	0.19
	8	7.84	0.37	7.74	0.48	7.83	0.37	7.85 ^a	0.68	7.67 ^a	1.03	8.16 ^a	0.3	7.76 ^a	0.08
	24	8-19 ^{b,c}	0.01	7.99	0.01	7.95 ^{<i>a</i>,b}	0.04	6.53 ^b	0.02	6.15 ^b	0.06	8.72 ^{b,c}	0.01	8.1 ^c	0.07

B-GOS, Bimuno[®] galacto-oligosaccharide.

^a Significantly different from 0 h with P<0.05; ^b significantly different from 4 h with P<0.05; ^c significantly different from 8 h with P<0.05; italicised superscript letters were significantly different with P<0.01; bold superscript letters were significantly different were significantly different

* The 65 % B-GOS and 52 % B-GOS were tested at 1, 0.5 and 0.33 g (equivalent to 0.1, 0.05 and 0.033 g/l).

Lactobacilli significantly increased after addition of 52 % B-GOS and 65 % B-GOS 1 and 0.33 g (equivalent to 0.1 and 0.033 g/l) (P<0.01) and 52 % B-GOS 0.5 g (equivalent to 0.05 g/l) (P<0.05) between 8 and 24 h. An overall decrease in the *Bacteroides–Provotella* group with 52 % B-GOS at doses of 1 and 0.33 g (equivalent to 0.1 and 0.033 g/l) was observed between 0 and 24 h (P<0.05). With 65 % B-GOS at 1 and 0.5 g (equivalent to 0.1 and 0.05 g/l), there was a significant decrease between 4 and 24 and 0 and 4 h, respectively (P<0.05). Twoway ANOVA data analyses did not show significant differences in microbiota composition between the two substrates.

Discussion

The present study was carried out in order to evaluate the *in vitro* fermentation properties of B-GOS (65% GOS content) in pH- and volume-controlled batch culture fermentation. The fermentability and the selectivity of GOS have been previously evaluated *in vitro*

by several comparative studies. Rycroft *et al.*⁽¹⁵⁾ compared the efficacy of different prebiotics including FOS and GOS in 24-h batch culture experiments, and the results show how GOS induced the largest significant increases in bifdobacteria, lactobacilli and total bacterial numbers during fermentation⁽¹⁵⁾. In our study, the administration of B-GOS showed the same trend, especially considering the bifdobacteria and lactobacilli population. There was also a significant decrease in *Bacteroidetes* numbers, except for 52% B-GOS at 0.05 g/l and 65% B-GOS at 0.033 g/l. The 65% B-GOS also has a strong influence in the production of SCFA, compared with B-GOS that is commercially available (52% GOS content). Our results showed a double increase in acetate production at all doses using 65% B-GOS, but were not significant, except for 65% B-GOS at 0.033 g/l, probably due to the high standard deviation.

The fermentation of all different doses induced the production of acetate, which correlated with an increase in *Bifidobacterium* populations⁽²⁴⁾. Palframan *et al.*⁽²⁵⁾ in a study comparing the effect of the pH and dose on batch culture fermentation of five commercial prebiotics have shown similar results. FISH analysis showed how the highest bacterial numbers were obtained with GOS at pH 6 and $1\% (w/v)^{(25)}$. The global effect on the bacterial population of 52% B-GOS has been tested in a previous fermentation study where the commercial B-GOS mixture was compared with different purified GOS. Using the Selectivity Index (SI) as a value for the growth of beneficial bacteria, Rodriguez-Colinas *et al.*⁽²⁶⁾ have shown that 52% B-GOS had the highest SI, and consequently a strong degree of selectivity for *Bifidobacterium* population.

Our results highlighted that 65% GOS had an effective prebiotic activity, in terms of increasing the number of bifidobacteria and metabolite production. This was especially seen for acetate, probably due to the lower content of monosaccharides and disaccharides in the mixture that might have affected *in vitro* fermentation experiments overall. However, a previous study of Costabile *et al.*⁽²⁷⁾ has demonstrated that the carbohydrates that remained after the *in vitro* pre-digestion process did not have any selective properties to invoke a bifidogenic effect, which perhaps would not persist *in vivo*⁽²⁸⁾.

In our study, major changes in other bacterial populations were seen, which might be due to the presence of these sugars. Different concentrations of SCFA have been identified at time 0, but it may be explained by the high inter-individual variability among each individual. Significant differences were observed between the time points in all analyses but not between the two substrates.

The effects of B-GOS 52% as a potential modulator of the gut microflora and the immune system have been extensively investigated in several human intervention studies. The 65% B-GOS has shown a significant modulation of health-promoting beneficial bacteria, and our findings proved that reducing impurities in the prebiotic mixture might improve the selectivity of prebiotics in *in vitro* experiments. However, the comparison between the effect of 65% B-GOS and 52% B-GOS has shown similar bifidogenic effects (data not published). The applicability of such changes remains to be investigated in *in vivo* human intervention studies.

Acknowledgements

R. G. carried out the experiments and drafted the manuscript. J. R. S. assisted with NMR analyses. G. R. G. and A. C. were involved in designing and coordination of the study and revising the manuscript critically for important intellectual content. J. V. assisted in designing the study and is employed by Clasado Biosciences Ltd, who provided the B-GOS product, marketed as Bimuno[®], used within this research. There are no patents, products in development or other marketed products to declare. This does not alter the authors adherence to all the *British Journal of Nutrition* policies on sharing data and materials. All the authors reviewed the final version of the manuscript.

The authors declare that there are no conflicts of interest.

References

 Sangwan V, Tomar SK, Singh RRB, *et al.* (2011) Galactooligosaccharides: novel components of designer foods. *J Food Sci* 76, 103–111.

- Tzortzis G & Vulevic J (2009) Galacto-oligosaccaride prebiotics. *Prebiotics Probiotics Sci Technol* 1, 207–244.
- Matsuki T, Watanabe K, Fujimoto J, *et al.* (2004) Quantitative PCR with 16s rRNA-gene-targeted species-specific primers for analysis of human intestinal bifidobacteria. *Appl Environ Microbiol* **70**, 167–173.
- Hernandez O, Ruiz-Matute AI, Olano A, *et al.* (2009) Comparison of fractionation techniques to obtain prebiotic galactooligosaccharides. *Int Dairy J* 19, 531–536.
- Tzortzis G (2009) Development and functional properties of Bimuno: a second-generation prebiotic mixture. *Food Sci Technol Bull* 6, 81–89.
- Goulas TK, Tzortis G & Gibson RG (2007) Development of a process for the production and purification of a- and b-galactooligosaccharides from *Bifidobacterium bifidum* NCIMB 41171. *Int Dairy J* 17, 648–656.
- Tzortzis G, Goulas AK & Gibson GR (2005) Synthesis of prebiotic galactooligosaccharides using whole cells of a novel strain, *Bifidobacterium bifidum* NCIMB 4117. *Appl Microbial Biotechnol* 68, 412–416.
- Schmidt K, Cowen PJ, Harmer CJ, *et al.* (2014) Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. *Psychopharmacology* 232, 1793–1801.
- Depeint F, Tzortzis G, Vulevic J, *et al.* (2008) Prebiotic evaluation of a novel galacto-oligosaccharide mixture produced by the enzymatic activity of *Bifidobacterium bifidum* NCIMB 41171, in healthy human: a randomized, double-blind, crossover, placebo-controlled intervention study. *Am J Clin Nutr* 87, 785–791.
- Drakoularakou A, Tzortzis G, Rastall RA, *et al.* (2010) A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers' diarrhoea. *Eur J Clin Nutr* 64, 146–152.
- Silk DBA, Davis A, Vulevic J, *et al.* (2009) Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable Bowel syndrome. *Aliment Pharmacol Ther* 29, 508–518.
- Vulevic J, Drakoularakou A, Yaqoob P, *et al.* (2008) Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. *Am J Clin Nutr* **88**, 1438–1446.
- Vulevic J, Juric A, Tzortzis G, *et al.* (2013) A mixture of transgalactooligosaccharides reduces markers of metabolic syndrome and modulates the faecal microbiota and immune function of overweight adults. *J Nutr* 143, 324–331.
- 14. Tzortzis G (2005) A novel Galactooligosaccharide mixture increases the Bifidobacterial population numbers in a continuous *in vitro* fermentation system and in the proximal colonic contents of Pigs *in vivo. J Nutr* **135**, 1726–1731.
- Rycroft CE, Jones MR, Gibson GR, *et al.* (2001) Fermentation properties of gentio-oligosaccharides. *J Appl Microbiol* **32**, 156–161.
- Costabile A, Kolida S, Gietl E, *et al.* (2010) A double-blind, placebo-controlled, cross-over study to establish the bifidogenic effect of a very-long-chain inulin extracted from globe artichoke (*Cynara scolymus*) in healthy human subjects. *Br J Nutr* **104**, 1007–1017.
- 17. Langendijk PS, Schut F, Jansen GJ, *et al.* (1995) Quantitative fluorescent *in situ* hybridisation of *Bifidobacterium* spp. with genus specific 16S rRNA targeted probes and its application in fecal samples. *Appl Environ Microbiol* **61**, 3069–3075.
- Manz W, Amann R, Ludwig W, *et al.* (1996) Application of a suite of 16S rRNA-specific oligonucleotide probes designed to investigate bacteria of the phylum cytophaga-flavobacter-bacteroides in the natural environment. *Microbiology* 142, 1097–1106.

486

- Harmsen HJM, Elfferich P, Schut F, *et al.* (1999) A 16S rRNAtargeted probe for detection of lactobacilli and enterococci in faecal samples by fluorescent *in situ* hybridization. *Microb Ecol Health Dis* 11, 3–12.
- Franks AH, Harmsen HJM, Raangs GC, *et al.* (1998) Variations of bacterial populations in human feces measured by fluorescent *in situ* hybridization with group specific 16S rRNAtargeted oligonucleotide probes. *Appl Environ Microbiol* 64, 3336–3345.
- 21. Daims H, Brühl A, Amann R, *et al.* (1999) The domain-specific probe EUB338 is insufficient for the detection of all Bacteria: development and evaluation of a more comprehensive probe set. *Syst Appl Microbiol* **22**, 434–444.
- Walker AW, Duncan SH, McWilliam Leitch EC, *et al.* (2005) pH and peptide supply can radically alter bacterial populations and short-chain fatty acid ratios within microbial communities from the human colon. *Appl Environ Microbiol* **71**, 3692–3700.

- Massot-Cladera M, Costabile A, Childs CE, *et al.* (2015) Prebiotic effects of cocoa fibre on rats. *J Funct Food* **19**, 341–352.
- Macfarlane GT, Steed H & Macfarlane S (2008) Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. *J Appl Microbiol* **104**, 305–344.
- Palframan RJ, Gibson GR & Rastall RA (2002) Effect of pH and dose on the growth of gut bacteria on prebiotic carbohydrates *in vitro. Anaerobe* 8, 287–292.
- Rodriguez-Colinas B, Kolida S, Baran M, *et al.* (2013) Analysis of fermentation selectivity of purified galacto-oligosaccharides by *in vitro* human faecal fermentation. *Appl Microbiol Biotechnol* 97, 5743–5752.
- 27. Costabile A, Santarelli S, Claus SP, *et al.* (2014) Effect of breadmaking process on *in vitro* gut microbiota parameters in irritable bowel syndrome. *PLOS ONE* **9**, e111225.
- Costabile A, Walton GE, Tzortzis G, *et al.* (2015) Effects of orange juice formulation on prebiotic functionality using an *in vitro* colonic model system. *PLOS ONE* **10**, e0121955.